Global Pulmonary Surfactant Market

Pulmonary Surfactant Comprehensive Study by Type (Synthetic Pulmonary Surfactants, Animal Derived Surfactants), Application (Hospital, Laboratory, Others), End User (Adults, Children) Players and Region - Global Market Outlook to 2026

Pulmonary Surfactant Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Pulmonary Surfactant Market?

Pulmonary surfactant is a complex mixture of phospholipids (PL) and proteins (SP) that reduce surface tension at the air-liquid interface of the alveolus, thus preventing its collapse during end-exhalation. It also participates in innate host defense against inhaled pathogens. Pulmonary Surfactant generally is a surface-active lipoprotein complex that is formed by type II alveolar cells. Hydrophilic and hydrophobic regions have both proteins as well as lipids that make up the surfactant. Pulmonary surfactant is important at all times because it lines the alveoli to lower physical phenomena, thereby preventing atelectasis during breathing.

The market study is being classified by Type (Synthetic Pulmonary Surfactants and Animal Derived Surfactants), by Application (Hospital, laboratory and Others) and major geographies with country level break-up.

Boehringer Ingelheim (Germany), AbbVie (United States), Lyomark Pharma (Germany), Tekzima (Iran), ONY Biotech (United States), Abbott Laboratories (United States), Aviva Systems Biology (United States), Lifespan Biosciences (United States), Biomatik (United Sttaes), Biorbyt (United States) and Reddot Biotech (Canada) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Windtree Therapeutics, Inc. (United States), XpressBio (United States), Creative Diagnostics (United States) and Windtree Therapeutics (United States).

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Pulmonary Surfactant market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Pulmonary Surfactant market by Type, Application and Region.

On the basis of geography, the market of Pulmonary Surfactant has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Increasing Demand for Reducing the Surface Tension in the Alveoli of Lungs as well as Prevents the Collapsing Tendency of Lungs
  • Rising Need due to Reduce the Work Associated with Breathing

Market Trend
  • Rising Adoption for Preventing the Collapsing Tendency of Lungs

Restraints
  • Various Side Effects Like Skin Paleness, Endotracheal Ttube Obstruction, and Others

Opportunities
  • Increased Research and Development Around Respiratory Syndromes

Challenges
  • Lack of Awareness about Benefits of the Property Management Software


On 24th March 2020, Windtree Therapeutics, Inc. has announced it is planning to study its proprietary KL4 surfactant to potentially mitigate the pulmonary effects of severe COVID-19 infection.


Key Target Audience
Pulmonary Surfactant Manufacturers, Research Institutes and Hospitals, Research Organizations and Consulting Companies, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Others

Report Objectives / Segmentation Covered

By Type
  • Synthetic Pulmonary Surfactants
  • Animal Derived Surfactants
By Application
  • Hospital
  • laboratory
  • Others
By End User
  • Adults
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Demand for Reducing the Surface Tension in the Alveoli of Lungs as well as Prevents the Collapsing Tendency of Lungs
      • 3.2.2. Rising Need due to Reduce the Work Associated with Breathing
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness about Benefits of the Property Management Software
    • 3.4. Market Trends
      • 3.4.1. Rising Adoption for Preventing the Collapsing Tendency of Lungs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pulmonary Surfactant, by Type, Application, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pulmonary Surfactant (Value)
      • 5.2.1. Global Pulmonary Surfactant by: Type (Value)
        • 5.2.1.1. Synthetic Pulmonary Surfactants
        • 5.2.1.2. Animal Derived Surfactants
      • 5.2.2. Global Pulmonary Surfactant by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Laboratory
        • 5.2.2.3. Others
      • 5.2.3. Global Pulmonary Surfactant by: End User (Value)
        • 5.2.3.1. Adults
        • 5.2.3.2. Children
      • 5.2.4. Global Pulmonary Surfactant Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Pulmonary Surfactant: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Boehringer Ingelheim (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AbbVie (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Lyomark Pharma (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Tekzima (Iran)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. ONY Biotech (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Aviva Systems Biology (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Lifespan Biosciences (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biomatik (United Sttaes)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Biorbyt (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Reddot Biotech (Canada)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Pulmonary Surfactant Sale, by Type, Application, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pulmonary Surfactant (Value)
      • 7.2.1. Global Pulmonary Surfactant by: Type (Value)
        • 7.2.1.1. Synthetic Pulmonary Surfactants
        • 7.2.1.2. Animal Derived Surfactants
      • 7.2.2. Global Pulmonary Surfactant by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Laboratory
        • 7.2.2.3. Others
      • 7.2.3. Global Pulmonary Surfactant by: End User (Value)
        • 7.2.3.1. Adults
        • 7.2.3.2. Children
      • 7.2.4. Global Pulmonary Surfactant Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pulmonary Surfactant: by Type(USD Million)
  • Table 2. Pulmonary Surfactant Synthetic Pulmonary Surfactants , by Region USD Million (2015-2020)
  • Table 3. Pulmonary Surfactant Animal Derived Surfactants , by Region USD Million (2015-2020)
  • Table 4. Pulmonary Surfactant: by Application(USD Million)
  • Table 5. Pulmonary Surfactant Hospital , by Region USD Million (2015-2020)
  • Table 6. Pulmonary Surfactant Laboratory , by Region USD Million (2015-2020)
  • Table 7. Pulmonary Surfactant Others , by Region USD Million (2015-2020)
  • Table 8. Pulmonary Surfactant: by End User(USD Million)
  • Table 9. Pulmonary Surfactant Adults , by Region USD Million (2015-2020)
  • Table 10. Pulmonary Surfactant Children , by Region USD Million (2015-2020)
  • Table 11. South America Pulmonary Surfactant, by Country USD Million (2015-2020)
  • Table 12. South America Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 13. South America Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 14. South America Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 15. Brazil Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 16. Brazil Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 17. Brazil Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 18. Argentina Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 19. Argentina Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 20. Argentina Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 21. Rest of South America Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 24. Asia Pacific Pulmonary Surfactant, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 28. China Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 29. China Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 30. China Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 31. Japan Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 32. Japan Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 33. Japan Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 34. India Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 35. India Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 36. India Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 37. South Korea Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 38. South Korea Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 39. South Korea Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 40. Taiwan Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 41. Taiwan Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 42. Taiwan Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 43. Australia Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 44. Australia Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 45. Australia Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 49. Europe Pulmonary Surfactant, by Country USD Million (2015-2020)
  • Table 50. Europe Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 51. Europe Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 52. Europe Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 53. Germany Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 54. Germany Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 55. Germany Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 56. France Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 57. France Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 58. France Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 59. Italy Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 60. Italy Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 61. Italy Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 62. United Kingdom Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 65. Netherlands Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 66. Netherlands Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 67. Netherlands Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 68. Rest of Europe Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 71. MEA Pulmonary Surfactant, by Country USD Million (2015-2020)
  • Table 72. MEA Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 73. MEA Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 74. MEA Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 75. Middle East Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 76. Middle East Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 77. Middle East Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 78. Africa Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 79. Africa Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 80. Africa Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 81. North America Pulmonary Surfactant, by Country USD Million (2015-2020)
  • Table 82. North America Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 83. North America Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 84. North America Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 85. United States Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 86. United States Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 87. United States Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 88. Canada Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 89. Canada Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 90. Canada Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 91. Mexico Pulmonary Surfactant, by Type USD Million (2015-2020)
  • Table 92. Mexico Pulmonary Surfactant, by Application USD Million (2015-2020)
  • Table 93. Mexico Pulmonary Surfactant, by End User USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Pulmonary Surfactant: by Type(USD Million)
  • Table 106. Pulmonary Surfactant Synthetic Pulmonary Surfactants , by Region USD Million (2021-2026)
  • Table 107. Pulmonary Surfactant Animal Derived Surfactants , by Region USD Million (2021-2026)
  • Table 108. Pulmonary Surfactant: by Application(USD Million)
  • Table 109. Pulmonary Surfactant Hospital , by Region USD Million (2021-2026)
  • Table 110. Pulmonary Surfactant Laboratory , by Region USD Million (2021-2026)
  • Table 111. Pulmonary Surfactant Others , by Region USD Million (2021-2026)
  • Table 112. Pulmonary Surfactant: by End User(USD Million)
  • Table 113. Pulmonary Surfactant Adults , by Region USD Million (2021-2026)
  • Table 114. Pulmonary Surfactant Children , by Region USD Million (2021-2026)
  • Table 115. South America Pulmonary Surfactant, by Country USD Million (2021-2026)
  • Table 116. South America Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 117. South America Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 118. South America Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 119. Brazil Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 120. Brazil Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 121. Brazil Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 122. Argentina Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 123. Argentina Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 124. Argentina Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 125. Rest of South America Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 127. Rest of South America Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 128. Asia Pacific Pulmonary Surfactant, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 131. Asia Pacific Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 132. China Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 133. China Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 134. China Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 135. Japan Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 136. Japan Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 137. Japan Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 138. India Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 139. India Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 140. India Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 141. South Korea Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 142. South Korea Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 143. South Korea Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 144. Taiwan Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 145. Taiwan Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 146. Taiwan Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 147. Australia Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 148. Australia Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 149. Australia Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 153. Europe Pulmonary Surfactant, by Country USD Million (2021-2026)
  • Table 154. Europe Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 155. Europe Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 156. Europe Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 157. Germany Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 158. Germany Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 159. Germany Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 160. France Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 161. France Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 162. France Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 163. Italy Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 164. Italy Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 165. Italy Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 166. United Kingdom Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 168. United Kingdom Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 169. Netherlands Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 170. Netherlands Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 171. Netherlands Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 172. Rest of Europe Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 174. Rest of Europe Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 175. MEA Pulmonary Surfactant, by Country USD Million (2021-2026)
  • Table 176. MEA Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 177. MEA Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 178. MEA Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 179. Middle East Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 180. Middle East Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 181. Middle East Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 182. Africa Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 183. Africa Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 184. Africa Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 185. North America Pulmonary Surfactant, by Country USD Million (2021-2026)
  • Table 186. North America Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 187. North America Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 188. North America Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 189. United States Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 190. United States Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 191. United States Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 192. Canada Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 193. Canada Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 194. Canada Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 195. Mexico Pulmonary Surfactant, by Type USD Million (2021-2026)
  • Table 196. Mexico Pulmonary Surfactant, by Application USD Million (2021-2026)
  • Table 197. Mexico Pulmonary Surfactant, by End User USD Million (2021-2026)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pulmonary Surfactant: by Type USD Million (2015-2020)
  • Figure 5. Global Pulmonary Surfactant: by Application USD Million (2015-2020)
  • Figure 6. Global Pulmonary Surfactant: by End User USD Million (2015-2020)
  • Figure 7. South America Pulmonary Surfactant Share (%), by Country
  • Figure 8. Asia Pacific Pulmonary Surfactant Share (%), by Country
  • Figure 9. Europe Pulmonary Surfactant Share (%), by Country
  • Figure 10. MEA Pulmonary Surfactant Share (%), by Country
  • Figure 11. North America Pulmonary Surfactant Share (%), by Country
  • Figure 12. Global Pulmonary Surfactant share by Players 2020 (%)
  • Figure 13. Global Pulmonary Surfactant share by Players (Top 3) 2020(%)
  • Figure 14. Global Pulmonary Surfactant share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 17. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 18. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 19. AbbVie (United States) Revenue: by Geography 2020
  • Figure 20. Lyomark Pharma (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Lyomark Pharma (Germany) Revenue: by Geography 2020
  • Figure 22. Tekzima (Iran) Revenue, Net Income and Gross profit
  • Figure 23. Tekzima (Iran) Revenue: by Geography 2020
  • Figure 24. ONY Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 25. ONY Biotech (United States) Revenue: by Geography 2020
  • Figure 26. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 28. Aviva Systems Biology (United States) Revenue, Net Income and Gross profit
  • Figure 29. Aviva Systems Biology (United States) Revenue: by Geography 2020
  • Figure 30. Lifespan Biosciences (United States) Revenue, Net Income and Gross profit
  • Figure 31. Lifespan Biosciences (United States) Revenue: by Geography 2020
  • Figure 32. Biomatik (United Sttaes) Revenue, Net Income and Gross profit
  • Figure 33. Biomatik (United Sttaes) Revenue: by Geography 2020
  • Figure 34. Biorbyt (United States) Revenue, Net Income and Gross profit
  • Figure 35. Biorbyt (United States) Revenue: by Geography 2020
  • Figure 36. Reddot Biotech (Canada) Revenue, Net Income and Gross profit
  • Figure 37. Reddot Biotech (Canada) Revenue: by Geography 2020
  • Figure 38. Global Pulmonary Surfactant: by Type USD Million (2021-2026)
  • Figure 39. Global Pulmonary Surfactant: by Application USD Million (2021-2026)
  • Figure 40. Global Pulmonary Surfactant: by End User USD Million (2021-2026)
  • Figure 41. South America Pulmonary Surfactant Share (%), by Country
  • Figure 42. Asia Pacific Pulmonary Surfactant Share (%), by Country
  • Figure 43. Europe Pulmonary Surfactant Share (%), by Country
  • Figure 44. MEA Pulmonary Surfactant Share (%), by Country
  • Figure 45. North America Pulmonary Surfactant Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Boehringer Ingelheim (Germany)
  • AbbVie (United States)
  • Lyomark Pharma (Germany)
  • Tekzima (Iran)
  • ONY Biotech (United States)
  • Abbott Laboratories (United States)
  • Aviva Systems Biology (United States)
  • Lifespan Biosciences (United States)
  • Biomatik (United Sttaes)
  • Biorbyt (United States)
  • Reddot Biotech (Canada)
Additional players considered in the study are as follows:
Windtree Therapeutics, Inc. (United States) , XpressBio (United States) , Creative Diagnostics (United States) , Windtree Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 250 Pages 51 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pulmonary Surfactant Market Quantitative research analysis
Global Pulmonary Surfactant Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increasing Demand for Reducing the Surface Tension in the Alveoli of Lungs as well as Prevents the Collapsing Tendency of Lungs " is seen as one of major growth factors of Pulmonary Surfactant Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.

Know More About Global Pulmonary Surfactant Market Report?

Have a Query? Click Here

Other Related Reports

Cancer Supportive Care Drugs Comprehensive Study by Application (Chemotherapy Therapy, Radiation Therapy), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies), Cance...
$ 3750
Botanical and Plant Derived Drugs Comprehensive Study by Type (Tablets, Capsules, Pills, Injections), Application (Central Nervous System, Cardiovascular Diseases, Infectious Diseases, Respiratory Di...
$ 3750
Ashwagandha Extract Comprehensive Study by Application (Sports Nutrition, Food & Beverages, Dietary Supplements, Other), Source (Root, Leaves, Others), Extract Percentage (Ashwagandha Extract 1.5%, ...
$ 3650
Fosfomycin Sodium Comprehensive Study by Type (Tablets, Injection), Application (Common Urinary Tract Infection, Postoperative Urinary Tract Infection, Preoperative Prevention of Urinary Tract Infect...
$ 3650
Clarithromycin Tablets Comprehensive Study by Type (250 mg Tablets, 500 mg Tablets), Application (Dermatology, ENT, Pediatric, Thoracic and Cardiovascular, Pulmonary Medicine), Distribution Channel (...
$ 3350
D-Calcium Pantothenate Comprehensive Study by Type (Food Grade, Pharma Grade, Feed Grade), Application (Food Industry, Cosmetic Industry, Pharmaceuticals Industry, Feed Industry, Other) Players and R...
$ 3500